<a class="info_title emj" href="https://togetter.com/li/1044342" title="IDWeek2016 ある薬剤師の視点から">IDWeek2016 ある薬剤師の視点から

How to measure "appropriateness" of #antimicrobial use- another challenging area of #antimicrobialstewardship @idweek2016

2016-10-28 00:53:41

Elizabeth Hermsen @ehermsenUSA

#IDWeek2016 On defining appropriate abx-"reduction of DDD or DOT is surrogate of improved appropriateness". Problem: 0 DOT=100% appropriate?

2016-10-28 01:00:57

How do you define inappropriate abx use? All star stewardship panel offers suggestions. Maybe even change the terminology? #IDWeek2016 pic.twitter.com/XhIiQkywew

2016-10-28 01:00:59

拡大

Dr. Malani demonstrates impact of an ASP bundle on optimizing treatment of #cdiff @idweek2016 ncbi.nlm.nih.gov/m/pubmed/26661… pic.twitter.com/nBcWOeGAwd

2016-10-28 01:04:25

拡大

Carlos del Rio @CarlosdelRio7

In COPD we see increase in Fermicutes and decrease in Bacteroides. -#IDWeek2016

2016-10-28 01:08:23

Outcome-measures are very different than outcomes. We do not have tangible ways to get meaningful data. CDI rates one of few things reported

2016-10-28 01:17:27

#IDWeek2016 stewardship panel shares metrics they follow. great question from @ASPphysician challenges us all "what about patient outcomes?" pic.twitter.com/96L1l3flAY

2016-10-28 01:18:44

拡大

Stewardship = mutlipronged goal. pts get treatment, decreased resistance, optimal drug use. Need multifaceted outcome to measure success.

2016-10-28 01:18:58

Don't just "check the box" when doing stewardship. Really think is the patient getting better? Outcome measures not perfect. #IDWeek2016

2016-10-28 01:21:26

Stanford Antimicrobial Stewardship @StanfordASP

Benchmarking suboptimal DOT/1000PD via Epic/Qlikview (Session 30: #74) #IDWeek2016 pic.twitter.com/5njaVD3zn6

2016-10-28 01:49:38

拡大

Carlos del Rio @CarlosdelRio7

Can FMT be also the treatment of choice for VRE and MDR GNRs? Need an RCT to test this hypothesis. #IDWeek2016

2016-10-28 01:53:50

"Can pharmacists have effective conversations with physicians about abx use?" #IDWeek2016 Variety of answers. Reply with yours!

2016-10-28 02:00:42

Chris Bland @blandman19

Relationships crucial to Stewardship initiatives. Takes time to develop. #idprn #IDWeek2016

2016-10-28 02:01:14

Jeremy Frens @FrensPharm

ASP can reduce relapse rates on staph bacteremia @jordraph @ClaeysKcclaeys pic.twitter.com/SzHvdULemT

2016-10-28 03:31:27

拡大

To prove AST equipment ($$) is value-added, need more studies! We have had molecular diagnostics for 10 years and ONE RCT to show impact.

2016-10-28 04:28:42

From 2015 VA study with 5000+ cases of bacteremia = Definitive therapy w/ Blactam significantly better than vanco for MSSA #IDWeek2016

2016-10-28 04:49:10

Duration of ABX for Infection: Less is more. For bacteremia? Unencumbered by data, need innovative trial design #idprn #IDWeek2016

2016-10-28 05:04:12

Jamie Wagner @jwagsIDPharmD

Dr Fowler on uncomplicated BSI durations: GNB = 5-14d Strep/Enterococci = 7-14d CoNS = 5-10d SAB = >= 14d #IDWeek2016

2016-10-28 05:27:37

Cliff Rutter, UKentucky #IDWeek2016 poster 302, nafcillin assoc. with increased AKI, mortality compared to cefazolin. pic.twitter.com/gORCDIO5sx

2016-10-28 05:57:04

拡大

Liz Highleyman @LizHighleyman

Judith Currier: nice overview of excess inflammation & immune activation in people w/#HIV, even on ART #IDWeek2016 pic.twitter.com/yOHh4mPXXv

2016-10-28 06:03:34

拡大

#IDWeek2016 poster 330, @mveveID Epi and outcomes of carbapenem-NS Pseudomonas and Enterobacteriaceae pic.twitter.com/U4bRG7jMak

2016-10-28 06:13:40

拡大

Dr. Cosgrove: interesting observation- as CAP guideline compliance increased, so did #cdiff rates. #idweek16

2016-10-28 23:52:48